Asthma, in general, is a respiratory disorder that affects millions of Americans each year.
Reasonably priced, effective treatments have been developed by several pharmacological
companies designed to treat this condition by various mechanisms. Levalbuterol has recently
been developed and marketed as a direct beta2 agonist with improved efficacy in symptom relief
as well as an improved side effect profile. A direct superiority study comparing side effect
profiles of both racemic albuterol and levalbuterol concluded that no significant improvement
was noticed with respect to side effect profiles between the two medications.